Navigation Links
NeoStem Announces Participation in Multiple January Conferences
Date:1/4/2012

NEW YORK, Jan. 4, 2012 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company and Progenitor Cell Therapy ("PCT"), will be presenting at four upcoming January conferences: Biotech Showcase 2012, BOCEMb 2012 - Noble Financial Capital Markets Equity Conference, ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies, and Phacilitate's Cell & Gene Therapy Forum 2012.

Dr. Robin L. Smith commented, "This list of January events demonstrates our widespread involvement in various industry forums and investor conferences that give us the opportunity to highlight our cell therapy industry expertise designed to put us at the forefront in transforming chronic disease through the application of cell based medicine while strategically providing revenues from our contract cGMP manufacturing of a variety of product candidates under development."

Biotech Showcase 2012 – January 10, 2012, San Francisco, California – Park 55 Wyndham8:00 – 9:30 AM – Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present as part of a panel discussion entitled "Regenerative Medicine State of the Industry Briefing."

10:30 AM – Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present on NeoStem in Track C.

9:30 – 11:00 AM – Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem, will present on Amorcyte, a NeoStem company developing novel treatments for cardiovascular disease, as part of a panel discussion entitled "Cardiovascular, AMI and PAD—Part 1".

ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies– January 11-13, 2012, San Diego, California – Catamaran Resort Hotel10:40 AM on Thursday, January 12 – Dr. Robert A. Preti, President of PCT, will chair a session titled "Process Development Challenges f
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeoStems CEO Letter to Shareholders
2. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
3. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
4. NeoStem Announces Participation in Multiple October Conferences
5. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSELā„¢ Technology Being Developed to Treat Osteoporosis
6. NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
7. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
8. NeoStem to Present at Two Investor Events This Month
9. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
10. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
11. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... DUBLIN , July 29, 2015 ... ) has announced the addition of the ... to their offering. The Global Biosimilars ... study of the rapidly growing biosimilars market. With ... industry striving to minimize costs, biosimilars are being ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... supply ordering system that allows users to create a ... order. ProSource then provides these items in one location ... order. ProSource eliminates the need to order from multiple ... from the same location, all while helping to eliminate ...
... CALGARY, Sept. 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... for metabolic and cardiovascular diseases, today announced that ... I/II human clinical trial of,plant-produced insulin now that ... (IND) application has passed. SemBioSys submitted,the application in ...
... Development of influenza VLP vaccines gains momentum with launch of ... IIa study of ... Inc.,(Nasdaq: NVAX ) announced today vaccination of healthy volunteers ... based seasonal influenza,vaccine. The Phase IIa randomized, placebo controlled clinical ...
Cached Biology Technology:ProSource 2.0 Offers Value, Savings for Lab Supplies 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... the breakdown of cognition processes and typical emotional and ... believe that several genes are associated with an increased ... the disease by itself. It is likely that interactions ... to develop and that epigenetic change also plays a ...
... Studies and the Woodrow Wilson International Center for Scholars ... Science Foundation (NSF) to help realize potential benefits and ... The grant is supported jointly by three ... Biology, the Division of Environmental Biology, and the Engineering ...
... generally deleterious, even in flowering plants. Since inbreeding raises ... be expressed, inbred progeny suffer from reduced viability. ... reject their own pollen, thereby preventing inbreeding despite the ... that involves the interaction of a gene that tags ...
Cached Biology News:How does inbreeding avoidance evolve in plants? 2
Roll of Mesh 5m x 25cm...
... Innovative HL-2000 HybriLinker combines the benefits of a ... self-contained, space saving unit. , ... Laboratory allows crosslinking ,and hybridization at one location ... HL-2000 operate independently of each other , ...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... Lambda Protein Phosphatase ( ... protein phosphatase with activity ... and tyrosine residues. It ... product of the ORF221 ...
Biology Products: